Ⅲ型慢性前列腺炎合并勃起功能障碍的中西医结合治疗临床观察

Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction

目的探讨花粉芪奴汤结合伐地那非治疗Ⅲ型慢性前列腺炎(CP/CPPS)合并勃起功能障碍(ED)的疗效。方法CP/CPPS合并ED患者138例,随机分为两组:治疗组70例,使用花粉芪奴汤4周后加用伐地那非治疗;对照组68例持续使用花粉芪奴汤8周。分别于第4和第8周末进行NIH-CPSI评分和ⅡEF-5评分观察疗效。结果4周末治疗组和对照组NIH-CPSI分别为13.1±4.7和13.3±4.5,较治疗前均显著下降(P<0.01),两组间比较差异无统计学意义(P>0.05),两组ⅡEF-5评分分别为14.1±3.3和14.3±5.0,较治疗前有所上升(P<0.01),但两组间比较差异无统计学意义(P>0.05)。8周后治疗组NIH-CPSI评分7.8±2.8、ⅡEF-5评分20.1±4.4与4周末比较差异均有统计学意义(P<0.01);对照组NIH-CPSI评分12.7±2.3、IIEF-5评分14.3±4.5、与4周末比较差异均无统计学意义(P>0.05);两组间NIH-CPSI与ⅡEF-5评分比较差异均有统计学意义(P<0.01),治疗组ⅡEF-5评分值与NIH-CPSI值呈负相关关系。结论对CP/CPPS合并ED患者在使用花粉芪奴汤加用伐地那非能有效治疗ED,同时使NIH-CPSI评分降低,促进CP/CPPS恢复。

Objective To evaluate the effects of Huafenqinutang combined with vardenafil for the treatment of chronic prostatitis/chronic pelvic pain syndrome （CP/CPPS） with erectile dysfunction. Methods One hundred and thirty-eight cases diagnosed as CP/CPPS with erectile dysfunction were randomized into trial group （70 cases） and control group （68 cases） for treatment with Huafenqinutang for 8 weeks, and in the former group, vardenaffil was added since the fifth weeks. All the cases were evaluated according to NIH-CPSI and IIEF-5 scores at 4 weeks and 8 weeks, respectively. Results At the end of the fourth weeks, NIH-CPSI score was 13.1±4.7 in the trial group and 13.3±4.5 in the control group, which were comparable between the two groups （P〉0.05） but significantly decreased compared with the pre-treatment scores in both groups （P〈0.01）. IIEF-5 score was also similar between the two groups （14.1±3.3 vs 14.3±5.0, P〉0.05） but significantly increased compared with the pre-treatment scores in both groups （P〈0.01）. At the end of the eighth week, NIH-CPSI score was 7.8±2.2 and IIEF-5 score 20.1±4.4 in the trial group, which were significantly different from those at the end of the fourth week （P〈0.01）. In the controlgroup, NIH-CPSI score was 12.7±2.3 and IIEF-5 score 14.3±4.5 at the eighth week, similar to those at the end of the fourth week （P〉0.05）. There were significant differences in NIH-CPSI and IIEF-5 scores between the 2 groups （P〈0.01）, and the change of NIH-CPSI score was negatively correlated with IIEF-5 score in the trial group （r=-0.89, P〈0.01）. Conclusion For patients with CP/CPPS with erectile dysfunction, Huafenqinutang treatment in combination with vardenafil can effectively improve the erectile functions and decrease the NIH-CPSI score to favor the recovery from CP/CPPS.